Oblique Therapeutics AB (publ) is a Swedish biotech company, developing innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company uses Abiprot™, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.